- 26 Jan 2021
- GeneQuine Biotherapeutics Secures More Than €9 Million in Series A Financing and Non-Dilutive Funding to Advance Gene Therapy Pipeline for Musculoskeletal Diseases
GeneQuine Biotherapeutics GmbH develops innovative gene therapies for the treatment of musculoskeletal disorders.
GeneQuine is focused on the development of local gene therapies for treatment of osteoarthritis - the most common joint disorder - and intervertebral disc degeneration - one of the major causes of chronic low back pain. Currently, there are only symptomatic drugs available for osteoarthritis and intervertebral disc degeneration disc disease. GeneQuine’s aim is to develop sustained, disease-modifying drugs for both indications that have a real impact on patients’ quality of life and mobility.
GeneQuine uses its gene therapy vector platform to establish sustained production of therapeutic proteins in affected tissues or organs after a single, local injection. This enables high-level and long-term (constant or adaptable) bioavailability of the therapeutic proteins where they are needed and at the same time minimizes exposure of the rest of the body to the drug.
GeneQuine is headquartered in Hamburg, Germany, with an R&D site in Luckenwalde (greater Berlin area), Germany, and a wholly-owned subsidiary in Belgium.